Skip to main content
S&P 5007,581.58+0.81%DOW52,200.56-0.06%NASDAQ25,369.06+1.21%BTC$73,637.00-0.65%ETH$2,054.61-1.03%GOLD$4,023.60-0.16%OIL$87.46+1.65%
Smart Investors Daily
SID Premium
RX

NASDAQ · RXRX

Recursion Pharmaceuticals, Inc. Class A Common Stock

Healthcare · Biotechnology

$3.55

Up+$0.03 (+0.83%)

Updated Nov 11, 2026, 2:55 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.83B
P/E ratio
-2.94
Dividend yield
0.00%
52-week range
$2.77 – $5.24
Volume
19.1M
Avg. volume
43.4M

Price performance · RXRX

RXRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

RXRX closed at $3.55 after 21 trading sessions, down 7.43% for the selected period.

Last close
$3.55
Period change
-7.43%
Period low
$3.47
Period high
$4.35
Daily close
View OHLC price history
RXRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$3.69$3.77$3.47$3.5519.1M
Nov 9, 2026$3.52$3.87$3.4701$3.80520.37M
Nov 6, 2026$3.585$3.645$3.48$3.5215.59M
Nov 5, 2026$3.79$3.795$3.42$3.5025.42M
Nov 4, 2026$3.83$4.01$3.72$3.8820.59M
Nov 3, 2026$3.855$4.08$3.65$3.6820.78M
Nov 2, 2026$4.11$4.17$3.78$3.8322.57M
Oct 30, 2026$4.05$4.1595$3.7847$4.0324.41M
Oct 29, 2026$4.25$4.515$4.15$4.2420.96M
Oct 28, 2026$4.00$4.43$3.9927$4.3528.5M
Oct 27, 2026$3.81$4.145$3.7301$4.0522.17M
Oct 26, 2026$3.71$3.86$3.64$3.8016.1M
Oct 23, 2026$3.52$3.70$3.45$3.7019.08M
Oct 22, 2026$3.54$3.68$3.485$3.5817.74M
Oct 21, 2026$3.66$3.76$3.56$3.6419.36M
Oct 20, 2026$3.555$3.67$3.47$3.6620.93M
Oct 19, 2026$3.53$3.69$3.48$3.6130.01M
Oct 16, 2026$4.11$4.185$3.44$3.46540.72M
Oct 15, 2026$3.65$4.41$3.53$4.1662.87M
Oct 14, 2026$3.72$3.91$3.66$3.7418.78M
Oct 13, 2026$4.01$4.05$3.82$3.83519.76M

Latest RXRX news

The latest Smart Investors Daily articles mentioning RXRX.

Stock researchCompany · Overview

RXRX research

Overview

Company profile and research snapshot.

Company profile

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.75
Implied upside
—
Analysts
—
RXRX recent ratings
DateFirmRatingTarget
Oct 19, 2026NeedhamBuy—
May 14, 2026Morgan StanleyEqual-Weight—
May 7, 2026NeedhamBuy—
Apr 30, 2026JP MorganOverweight—
Feb 26, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing

AI-driven toxicology cuts testing time and costs, improves accuracy, reduces animal testing, and strengthens early risk detection and regulatory compliance.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "AI in Predictive Toxicology - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering The global artificial intelligence (AI) in predictive toxicology market was valued at US$584 million in 2025 and is projected to reach US$3.2 billion by 2032, expanding at a compou

Yahoo · Nov 5, 2026

Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?

Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just delivered a busy Q3 2026, pairing an earnings update and ongoing losses with fresh clinical data and leadership changes that give investors more to unpack around the stock. For context, Recursion Pharmaceuticals has seen choppy trading this year, with a 1-day share price return of 5.43% to US$3.88 after the Q3 release, compared with a 30-day share price decline of 18.83% and a...

Yahoo · Nov 5, 2026

REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals reported Q3 2026 revenue of US$18.55 million and a net loss of US$119.04 million, while highlighting an extended cash runway into 2029, new financing and ongoing pharma collaborations. Fresh Phase 2 data for REC-4881 in familial adenomatous polyposis showed meaningful and durable reductions in polyp burden with a generally manageable safety profile, reinforcing the clinical relevance of Recursion Pharmaceuticals' AI-driven discovery platform. The focus now turns to...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By